<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02832206</url>
  </required_header>
  <id_info>
    <org_study_id>PRAGUE-21</org_study_id>
    <nct_id>NCT02832206</nct_id>
  </id_info>
  <brief_title>Hybrid Ablation of Persistent and Long-standing Persistent Stand-alone Atrial Fibrillation</brief_title>
  <official_title>EndoMaze HYBRID project-a Detailed Assessment of Efficacy and Safety of Hybrid Ablation of Persistent and Long-standing Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles University, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charles University, Czech Republic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates in detail efficacy and safety (including neurological safety) of hybrid&#xD;
      ablation of stand-alone, persistent and long-standing persistent atrial fibrillation (AF). An&#xD;
      implantable ECG monitor will be implanted to all patients for rhythm monitoring. Neurological&#xD;
      safety will be assessed by cerebral magnetic resonance, neuropsychological examination and&#xD;
      periprocedural transcranial Doppler measurement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hybrid ablation (i.e. surgical thoracoscopic ablation, followed by catheter endocardial&#xD;
      ablation) represent a new treatment option for patients with atrial fibrillation.&#xD;
&#xD;
      60 patients will undergo a two-stage, hybrid ablation, all of them will have an ECG&#xD;
      monitoring device implanted and will be followed for up to three years. Neurological safety&#xD;
      of both surgical and catheter procedures will be assessed by three examinations. Magnetic&#xD;
      resonance will be performed before surgery, 5 days after surgery and at the 180 days visit to&#xD;
      search for (subclinical) cerebral ischemia. Complex neuropsychological examination will be&#xD;
      performed before surgery, afer 1 month after surgery and at 180 days visit to search for&#xD;
      changes in cognitive functions, behavioral functions etc. Transcranial Doppler will be&#xD;
      performed during surgical and catheter ablation to detect microembolic signals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Actual">December 10, 2019</completion_date>
  <primary_completion_date type="Actual">December 10, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>sinus rhythm (The Reveal LINQ Insertable Cardiac Monitoring System)</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients with sinus rhythm, without detections of atrial arrhythmias (episodes longer than 30 seconds)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>neurological safety (cerebral magnetic resonance (MR), neuropsychological changes - multiple questionnaires, Transcranial Doppler)</measure>
    <time_frame>180 days</time_frame>
    <description>new ischaemic brain lesions on MR performed at the discharge from surgery and at the 180 days visit), neuropsychological changes measured by special questionnaires, that will be filled at 30 and 180 days visit, periprocedural Doppler - hits rates on periprocedural transcranial Doppler measurement during both surgery and catheter ablation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>periprocedural complications - surgery</measure>
    <time_frame>30 days</time_frame>
    <description>conversion to sternotomy, bleeding, thromboembolic events, tamponade, haemothorax, pneumothorax, pleural effusion, pneumonia</description>
  </secondary_outcome>
  <other_outcome>
    <measure>QoL measurement</measure>
    <time_frame>1 year</time_frame>
    <description>changes in quality of life, measured by questionnaires AFEQT</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">59</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>hybrid ablation</arm_group_label>
    <description>60 patients with stand-alone, persistent or long-standing persistent atrial fibrillation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hybrid ablation</intervention_name>
    <description>Surgical thoracoscopic epicardial ablation (box-lesion) and left atrial appendage occlusion , followed (after 2-3months) by electrophysiological examination, and catheter ablation (completion of the box-lesion, cavotricuspid isthmus ablation and other ablation if indicated)</description>
    <arm_group_label>hybrid ablation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with symptomatic, drug-resistant, stand-alone, persistent or long-standing&#xD;
        persistent atrial fibrillation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients age &gt; 18 years&#xD;
&#xD;
          -  Patients with persistent/long-standing persistent AF according to the standard EHRA&#xD;
             definition.&#xD;
&#xD;
          -  Patients with symptomatic AF that is refractory to at least one antiarrhythmic&#xD;
             medication.&#xD;
&#xD;
          -  Absence of significant structural heart disease (dilated cardiomyopathy, hypertrophic&#xD;
             cardiomyopathy, valvular heart disease, untreated coronary artery disease)&#xD;
&#xD;
          -  Ability to sign an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Paroxysmal AF&#xD;
&#xD;
          -  AF secondary to a reversible cause (i.e., thyreopathy, etc.)&#xD;
&#xD;
          -  Indication for open-heart surgery (coronary artery bypass grafting, valve surgery,&#xD;
             etc.)&#xD;
&#xD;
          -  Severe left ventricle dysfunction that is clearly caused by some other cardiac disease&#xD;
             (dilated cardiomyopathy, ischaemic heart disease, etc.) where the AF is clearly of&#xD;
             secondary etiology&#xD;
&#xD;
          -  Known severe pericardial and pleural adhesions (e.g., history of cardiac surgery)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zbynek Straka, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Kralovske Vinohrady</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charles University, Third Faculty of Medicine</name>
      <address>
        <city>Prague</city>
        <zip>10000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 29, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charles University, Czech Republic</investigator_affiliation>
    <investigator_full_name>Petr Budera</investigator_full_name>
    <investigator_title>M.D., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Hybrid ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

